- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03096288
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity
Clopidogrel is the most widely used P2Y12 receptor inhibitor and is the only agent of this class currently recommended in patients with stable coronary artery disease (CAD) undergoing PCI, and for the treatment of stroke or PAD. Pharmacodynamic (PD) studies have shown that approximately 30-40% of patients experience high on-treatment platelet reactivity (HPR) while receiving clopidogrel treatment. Importantly HPR status has been strongly associated with an increased risk of ischemic events. Multiple approaches have been advocated to reduce HPR rates. In a previous study treatment with high-dose atorvastatin in addition to double-dose clopidogrel reduced platelet reactivity significantly more than double-dose clopidogrel alone in statin-naïve patients with stable CAD and HPR. To date, the exact biological mechanisms involved in the statin modulation of platelet function are not fully understood, although likely attributed to both its lipid-lowering and non-lipid-related effects.
Evolocumab is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). The use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced the incidence of cardiovascular events. Whether the reduction in cardiovascular events is simply due to LDL reduction or might be related to other mechanisms is currently subject of investigation. Although LDL reduction with statin therapies has been associated with reduction in platelet reactivity, to date the effects on platelet aggregation of adjunctive lipid lowering with evolocumab has not been explored.
The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on HPR rates and platelet reactivity in patients with atherosclerotic cardiovascular disease (ASCVD) and HPR while on clopidogrel treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Clopidogrel is the most widely used P2Y12 receptor inhibitor and is the only agent of this class currently recommended in patients with stable coronary artery disease (CAD) undergoing PCI, and for the treatment of stroke or PAD. Although the efficacy of DAPT with aspirin and clopidogrel has been consistently shown in different clinical settings, rates of ischemic recurrences remain elevated despite this treatment regimen, especially in high risk patients. This has been in part attributed to the high interindividual variability in responses to clopidogrel. Pharmacodynamic (PD) studies have shown that approximately 30-40% of patients experience high on-treatment platelet reactivity (HPR) while receiving clopidogrel treatment. Importantly HPR status has been strongly associated with an increased risk of ischemic events, in particular stent thrombosis, in patients with ACS and following PCI. This underscores the need for strategies aimed to reduce HPR rates in patients treated with clopidogrel. Multiple approaches have been advocated to reduce HPR rates. The pleiotropic effects associated with lipid lowering therapies, in particular statins, have been subject to extensive research. In a previous study treatment with high-dose atorvastatin in addition to double-dose clopidogrel reduced platelet reactivity significantly more than double-dose clopidogrel alone in statin-naïve patients with stable CAD and HPR. To date, the exact biological mechanisms involved in the statin modulation of platelet function are not fully understood, although likely attributed to both its lipid-lowering and non-lipid-related effects.
Evolocumab is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously (s.c.) at a dosage of 140 mg every 2 weeks or 420 mg once monthly. In clinical trials evolocumab was more effective than placebo and/or ezetimibe in reducing LDL cholesterol, including when added to statin therapy. The use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced the incidence of cardiovascular events. Whether the reduction in cardiovascular events is simply due to LDL reduction or might be related to other mechanisms is currently subject of investigation. Although LDL reduction with statin therapies has been associated with reduction in platelet reactivity, to date the effects on platelet aggregation of adjunctive lipid lowering with evolocumab has not been explored.
The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on HPR rates and platelet reactivity in patients with atherosclerotic cardiovascular disease (ASCVD) and HPR while on clopidogrel treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with atherosclerotic cardiovascular disease (ASCVD), defined as prior ACS, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or PAD presumed to be of atherosclerotic origin.
- On therapy with clopidogrel (75mg od), with or without low-dose aspirin (81mg od), as per standard-of-care for at least 30 days.
- HPR, defined as P2Y12 reaction units (PRU) > 208 by VerifyNow P2Y12.
- Fasting LDL-cholesterol ≥70 mg/dL or a non-high-density lipoprotein cholesterol (HDL-C) of ≥100 mg/dL after ≥2 weeks of optimized stable lipid-lowering therapy with maximally tolerated dose of statin, which would ideally include a high-intensity statin, but must be at least moderate intensity statin (i.e. atorvastatin 20 mg or equivalent, with or without ezetimibe. Maximal tolerated dose will be defined based on patient clinical history (no statin re-challenge will be performed).
- Age ≥ 18 years old.
Exclusion criteria:
- On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban).
- On treatment with any antiplatelet agent other than aspirin and clopidogrel in the past 14 days.
- Use of PCSK9 inhibitors in the past 90 days
- Creatinine clearance <30 mL/minute.
- Known severe hepatic impairment.
- History of a serious hypersensitivity reaction to evolocumab
- Hemodynamic instability
- Pregnant and breastfeeding women [women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study].
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Evolocumab
Evolocumab (Repatha) 420 mg s.c.
single injection
|
Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c.
injection).
Other Names:
|
PLACEBO_COMPARATOR: Placebo
0.9% sodium chloride s.c.
single injection
|
Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c.
injection).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Platelet Reactivity Defined by VerifyNow PRU in HPR and NPR Patients
Time Frame: 30 days
|
The primary end point of our study is the comparison of P2Y12 reaction units (PRU) measured by VerifyNow between evolocumab and placebo at 30 days after randomization.
PRU is a well-established measure of platelet reactivity and aggregation in response to antiplatelet medications.
The higher is the PRU the lower is the effect of the antiplatelet medication.
HPR is defined as PRU>208 and NPR as PRU 85-208.
|
30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dominick Angiolillo, MD, PhD, University of Florida College of Medicine-Jacksonville
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIS AMG001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerotic Cardiovascular Disease
-
Novartis PharmaceuticalsNot yet recruitingElevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
-
Advanced Education & Research CenterUniversity of Karachi; Pakistan Cardiac Society (Heart House)RecruitingAtherosclerotic Cardiovascular Diseases (ASCVD)Pakistan
-
Novartis PharmaceuticalsCompletedAtherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein CholesterolUnited Kingdom
-
Eli Lilly and CompanyRecruitingElevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)United States, Taiwan, Canada, Argentina, China, Japan, Denmark, Australia, Brazil, Hungary, Mexico, Germany, Romania, Korea, Republic of, United Kingdom, Belgium, Czechia, India, Netherlands, Poland, Slovakia, France, Spain, Austria, Puerto...
-
AmgenRecruitingMajor Cardiovascular Event | Established Atherosclerotic Cardiovascular DiseaseChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Pauls Stradins Clinical University HospitalActive, not recruitingAtherosclerotic Cardiovascular DiseaseLatvia
-
Pieter MuntendamIcahn School of Medicine at Mount Sinai; AstraZenecaEnrolling by invitationHeart Diseases | Stroke | Plaque, Atherosclerotic | Cardiovascular Risk Factor | Atherosclerotic DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedObesity | Blood Pressure | Subclinical Atherosclerotic Cardiovascular DiseaseUnited States
-
Kahramanmaras Sutcu Imam UniversityCompletedCoronary Artery Disease | Progression of Atherosclerotic PlaqueTurkey
Clinical Trials on Evolocumab
-
Hospital General Universitario Gregorio MarañonCompleted
-
First Affiliated Hospital of Fujian Medical UniversityRecruiting
-
AmgenCompletedMixed Dyslipidemia | Primary HypercholesterolemiaUnited States, Canada
-
Rigshospitalet, DenmarkWithdrawnLipid Lowering, Vascular InflammationDenmark
-
AmgenOrganization of Teratology Information Specialists (OTIS) Research Center...TerminatedHypercholesterolemia; ASCVD; Pregnancy
-
AmgenCompletedMixed Dyslipidemia | Primary HypercholesterolemiaUnited States, Canada
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompleted
-
AmgenCompletedHomozygous Familial Hypercholesterolemia HoFHIndia
-
AmgenTerminatedMixed Dyslipidemia | Primary HypercholesterolemiaChina
-
LIB Therapeutics LLCCompletedHomozygous Familial HypercholesterolemiaUnited States, Israel, Norway, South Africa, Turkey, India